We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Luminex Corporation

Luminex develops, manufactures, and markets biological testing technologies with applications in clinical diagnostics... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Biomarkers Linked to Autism Risk Identified

By LabMedica International staff writers
Posted on 20 Jan 2022
Print article
Image: The Human Cytokine/Chemokine/Growth Factor Convenience 45-Plex ProcartaPlex Panel, 384 well (lyophilized beads) enables the study of immune function by analyzing 45 protein targets in a single well using Luminex FLEXMAP 3D and INTELLIFLEX instruments (Photo courtesy of Thermo Fisher Scientific)
Image: The Human Cytokine/Chemokine/Growth Factor Convenience 45-Plex ProcartaPlex Panel, 384 well (lyophilized beads) enables the study of immune function by analyzing 45 protein targets in a single well using Luminex FLEXMAP 3D and INTELLIFLEX instruments (Photo courtesy of Thermo Fisher Scientific)
Autism spectrum disorders (ASDs) comprise a set of pervasive neurodevelopmental conditions characterized by restricted and repetitive behavior patterns and impairments in social interaction and communication.

Cytokines regulate intrauterine immune responses, neurogenesis, neuronal migration, and synaptogenesis, and have the capacity to signal through cognate receptors on microglial cells and other neural components distributed throughout brain circuitry.

An international team of Infection and Immunology Specialists led by those at Columbia University (New York, NY, USA) identified molecular signatures of gestational inflammation linked to the risk of developing autism spectrum disorder (ASD). They analyzed the presence of 60 molecular markers of immune response, including cytokines and growth factors. Blood samples were collected during pregnancy (maternal mid-gestational blood sample) and at birth (cord blood) from 957 children, roughly half of whom were later diagnosed with ASD.

The team assayed a wide range of cytokines, chemokines, cellular, and growth factors reflecting key processes relating to systemic activation of inflammatory/immune signaling pathways involved in autoimmunity and anti-inflammatory responses as well as others implicated in CNS inflammation, neurovascular disruption, and neurogenesis. Immune molecules within this panel are also found to be dysregulated during infection with certain pathogens, including those that trigger autoimmunity, as well as in some studies in ASD. The scientists used a customized Procarta immunoassay (Affymetrix/eBioscience, Santa Clara, CA, USA). ProcartaPlex immunoassays are antibody-based, magnetic bead reagent kits and panels for multiplex protein quantitation using the Luminex instrument platform (Austin, TX, USA).

The investigator reported that their study linked ASD risk to groupings of inflammation-related molecules, with different groupings seen in boys versus girls. Among the most predictive molecules were interleukins like IL1RA and IL4. Four molecules thought to be involved in fetal brain development were also linked to ASD risk in both sexes: TNFα, Serpin E1, VCAM1, and IL1β. Biomarkers collected at birth were only slightly less predictive than those collected during pregnancy.

Mady Hornig, MD, an associate professor and a co-first author of the study, said, “We found immune signatures in mid-pregnancy blood samples from mothers and in umbilical cord blood from children later diagnosed with autism that correlate with responses to infection, and molecules important for the development of the brain and its blood supply.”

The authors concluded that their results provide robust evidence of immune dysregulation in mothers as early as 17–21 weeks gestation and in cord blood (CB) of neonates later diagnosed with ASD. The study was published on January 5, 2022 in the journal Molecular Psychiatry.

Related Links:
Columbia University
Affymetrix
Luminex


Gold Supplier
BMP Whole Blood Analyzer
GEM Premier ChemSTAT
New
Silver Supplier
Helicobacter Pylori Test
AB HP UREASE TEST
New
Automatic Photometer
JOLLY 103
New
Gold Supplier
NT-proBNP Quantitative Antigen Test
NT-proBNP-CHECK-1

Print article

Channels

Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Molecular Diagnostics

view channel
Image: This image depicts a DNA molecule that is methylated on both strands on the center cytosine. DNA methylation plays an important role for epigenetic gene regulation in development and cancer (Photo courtesy of Wikimedia Commons)

Study Supports Use of Methylated DNA Biomarkers for Cancer Diagnosis and Prognosis

A recent study added weight to the theory that methylated DNA biomarkers could be used for cancer diagnosis and prognosis. Methylation is a biological process by which methyl groups are added to a DNA molecule.... Read more

Hematology

view channel
Image: Standard test for multiple myeloma provides clues of a rare, more deadly type (Photo courtesy of Pexels)

Standard Blood Cancer Test Provides Clues of Rare IgD Multiple Myeloma

IgD myeloma accounts for about 1% of common blood cancer multiple myeloma and has a worse prognosis. Specific testing for IgD myeloma is available at a handful of reference labs across the US, but takes... Read more

Industry

view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.